| Title: | Neuroendocrine carcinoma of the larynx and pharynx : a clinical and histopathological study |
|---|
| Authors: | ID Strojan, Primož (Author)
ID Šifrer, Robert (Author)
ID Ferlito, Alfio (Author)
ID Grašič-Kuhar, Cvetka (Author)
ID Lanišnik, Boštjan (Author)
ID Plavc, Gaber (Author)
ID Zidar, Nina (Author) |
|---|
| Files: |  URL - Source URL, visit https://www.mdpi.com/2072-6694/13/19/4813
 PDF - Presentation file, download (3,97 MB)
MD5: 037DF31D4F05DA593B4B3B77E0C26075
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Neuroendocrine carcinomas (NECs) of the head and neck are rare and the experience scanty. The Cancer Registry of Slovenia database was used to identify cases of laryngeal and pharyngeal NECs diagnosed between 1995%2020. Biopsies were analyzed for the expression of standard neuroendocrine markers (synaptophysin, chromogranin, CD56), INSM1, Ki-67, p16, and PD-L1 (using the combined positive score, CPS). In situ hybridization for human papillomavirus (HPV) and Epstein%Barr virus (EBV) was performed. Twenty patients (larynx, 12; pharynx, 8) were identified. One tumor was well differentiated (WD), five were moderately differentiated (MD), and 14 were poorly differentiated (PD). Disease control was achieved solely by surgery in 4/4 MD/PD T1-2N0-1 tumors. Eight patients died of the disease, seven of which were due to distant metastases. All three traditional markers were positive in 11/17 NECs and the INSM1 marker in all 20 tumors. Two of fourteen p16-positive tumors were HPV-positive, but all three nasopharyngeal NECs were EBV-negative. Three tumors had CPSs % 1. In conclusion, INSM1 was confirmed to be a reliable marker of neuroendocrine differentiation. Except in WD and early-stage MD/PD tumors, aggressive multimodal therapy is needed; the optimal systemic therapy remains to be determined. p16, HPV, and EBV seem to bear no prognostic information. |
|---|
| Keywords: | electrochemotherapy, head and neck cancer, neuroendocrinic carcinoma |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 27.09.2021 |
|---|
| Place of publishing: | Basel |
|---|
| Publisher: | MDPI AG |
|---|
| Year of publishing: | 2021 |
|---|
| Number of pages: | str. [1-16] |
|---|
| Numbering: | Vol. 13, no. 19 |
|---|
| PID: | 20.500.12556/DiRROS-15455  |
|---|
| UDC: | 615.82/.84 |
|---|
| ISSN on article: | 2072-6694 |
|---|
| COBISS.SI-ID: | 79949315 |
|---|
| Copyright: | by Authors |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 3. 10. 2021;
|
|---|
| Publication date in DiRROS: | 07.09.2022 |
|---|
| Views: | 482 |
|---|
| Downloads: | 217 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
